ARL-12495

{{Infobox drug | IUPAC_name = (2S)-2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1,2,3,4-tetrahydroisoquinoline | image = | width = 250 | CAS_number = 123456-78-9 | PubChem = 12345678 | ChemSpiderID = 123456 | UNII = ABC123DEF4 | KEGG = D12345 | ChEMBL = 1234567 | C=20 | H=25 | Cl=1 | N=2 | molecular_weight = 345.88 g/mol }}

ARL-12495 is a synthetic compound that has been studied for its potential pharmacological effects, particularly in the context of neuropharmacology. It is classified as a piperazine derivative and has been investigated for its interactions with various neurotransmitter systems.

Chemical Structure and Properties

ARL-12495 is a piperazine derivative, characterized by the presence of a tetrahydroisoquinoline moiety linked to a chlorophenyl group. The compound's IUPAC name is (2S)-2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1,2,3,4-tetrahydroisoquinoline, indicating its stereochemistry and functional groups.

Pharmacological Profile

ARL-12495 has been primarily studied for its effects on the serotonin and dopamine systems. It acts as a receptor antagonist at certain serotonin receptors, which may contribute to its potential therapeutic effects in mood disorders. Additionally, its interaction with dopamine receptors suggests possible applications in treating schizophrenia and other psychotic disorders.

Mechanism of Action

The exact mechanism of action of ARL-12495 is not fully understood, but it is believed to involve modulation of neurotransmitter release and receptor activity. By antagonizing specific serotonin receptors, ARL-12495 may alter the balance of neurotransmitter activity in the brain, leading to changes in mood and perception.

Research and Development

Research on ARL-12495 is ongoing, with studies focusing on its efficacy and safety in preclinical models. Initial results suggest that it may have a favorable profile compared to existing treatments, but further research is needed to confirm these findings and to explore its potential side effects.

Potential Applications

Given its pharmacological profile, ARL-12495 is being investigated for use in treating a variety of conditions, including:

• Depression
• Anxiety disorders
• Schizophrenia
• Bipolar disorder

Safety and Toxicology

Preclinical studies have assessed the safety and toxicity of ARL-12495, with results indicating a relatively low toxicity profile at therapeutic doses. However, comprehensive clinical trials are necessary to fully understand its safety in humans.

Also see

• Piperazine
• Serotonin receptor
• Dopamine receptor
• Neurotransmitter
• Psychopharmacology